ArticleBone marrow transplantation2017
GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.
Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.International journal of hematology · 2021Trial
- Optimal dosage of methotrexate for GVHD prophylaxis in umbilical cord blood transplantation.International journal of hematology · 2019Trial
- GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.Blood advances · 2026Article
- Clinical and Histopathological Features of Oral Verruciform Xanthoma: A Case Series of Three Patients.Clinical case reports · 2026Article
- Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults.American journal of hematology · 2025Article
- Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia.Scientific reports · 2025Article
- Influence of interruption of oral mycophenolate mofetil for graft-versus-host disease prophylaxis on outcomes after single cord blood transplantation.Blood cell therapy · 2024Article
- Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score.Blood advances · 2024Article
- Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial.Annals of hematology · 2023Article
- Article
- Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.Bone marrow transplantation · 2022Article
- Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.Blood advances · 2022Article
- Role of NK cells in cord blood transplantation and their enhancement by the missing ligand effect of the killer-immunoglobulin like receptor.Frontiers in genetics · 2022Review
- Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.Bone marrow transplantation · 2021Article
- Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation.International journal of hematology · 2021Article
- Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients.International journal of hematology · 2021Article
- Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.Annals of hematology · 2021Article
- Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
- Article
- Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation.British journal of clinical pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate better GVHD prophylaxis in reduced intensity conditioning umbilical cord blood transplantation (RIC-UCBT), we compared transplant outcomes after UCBT among GvHD prophylaxes using the registry data. We selected patients transplanted for AML or ALL with a calcineurin inhibitor and methotrexate (MTX)/mycophenolate mofetil (MMF) combination. A total of 748 first RIC-UCBT between 2000 and 2012 (MTX+ group, 446, MMF+ group, 302) were included. The cumulative incidence of neutrophil and platelet counts higher than 50 000/μL was significantly better in the MMF+ group (relative risk (RR), 1.55; P<0.001: RR, 1.34; P=0.003, respectively). In multivariate analyses, the risk of grade II-IV and III-IV acute GvHD was significantly higher in the MMF+ group than in the MTX+ group (RR, 1.75; P<0.001: RR, 1.97; P=0.004, respectively). In disease-specific analyses of AML, the risk of relapse of high-risk disease was significantly lower in the MMF+ group (RR, 0.69; P=0.009), whereas no significant difference was observed in the risk of relapse-free and overall survival in high-risk disease. In patients with standard-risk disease, no significant differences were noted in the risk of relapse or survival between the MTX+ and MMF+ groups. Collectively, these results suggest that MMF-containing prophylaxis may be preferable in RIC-UCBT, particularly for high-risk disease.
Indexed as
Identifiers
28604665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.